Commission opens investigation into possible anticompetitive conduct by Sanofi regarding the promotion of a flu vaccine for vulnerable patients
What happened
The European Commission, on June 26, 2026, opened a formal antitrust investigation. This investigation assesses whether Sanofi breached EU competition rules. The alleged breach involves a communication campaign that disparaged the only rival flu vaccine recommended for vulnerable patients with risk factors.
Why it matters
This investigation could impact the competitive landscape for flu vaccines, particularly for vulnerable patients. It highlights the Commission's commitment to ensuring fair competition and protecting consumers from potentially anticompetitive practices in the pharmaceutical sector.
Who it affects
- ›Sanofi (pharmaceutical company)
- ›European Commission
- ›Patients with risk factors
- ›Rival flu vaccine manufacturers
The receipts are official. The summary is ours.
Read on European Commission ↗Summaries are generated from the official text and may simplify or omit nuance. The official document is the source of truth.